Chimeric Antigen Receptor Cell Therapy

2019-02-28
Price :
Published : Feb-2019
No. of Pages : 108

Chimeric Antigen Receptor Cell Therapy

Summary

Chimeric antigen receptor (CAR) cell therapy is an immuno-oncology (IO) approach that has gained increasing momentum in the past few years, with the approval of two new therapies in 2017 (US) and 2018 (EU). Novartis’ Kymriah (tisagenlecleucel) and Gilead Sciences’ Yescarta (axicabtagene ciloleucel) demonstrated impressive efficacy, and have both been approved for diffuse large B-cell lymphoma (DLBCL), with Novartis’ product approved for acute lymphocytic leukemia as well. Despite promising efficacy data, several challenges face the integration of CAR cell therapies into the clinic. Complex manufacturing can lead to delayed patient access, as currently approved therapies can take up to three weeks to manufacture. High toxicity is also a key challenge for CAR cell therapies, as high rates of cytokine release syndrome and neurotoxicities (which can be fatal) require constant patient monitoring, potentially limiting CAR cell therapy’s use to centers of excellence. High production cost and hefty pricing are also challenges that CAR cell developers fail, as payers may hold negative perceptions of the nearly $0.5M pricepoint per dose.

This report provides an overview of the approved and late-stage pipeline CAR cell therapy landscape (including pre-clinical and Phase I CAR-NK cells), as well as a summary of key regulation processes in place in the 8MM (France, Germany, Italy, Spain, UK, US, Japan, China). Key challenges faced by CAR cell therapies are summarized, as well as expected future development trends for the field.

Scope

Components of the slide deck include primary and secondary research –
– Quotes from eight US- and 5EU-based key opinion leaders, payers, and researchers
– Quotes from three Japan-based key opinion leaders
– Summary of CAR-cell therapy mechanism of action and history of development
– Overview of late-stage CAR cell pipeline and two marketed products
– Outline of regulatory pathways in place for CAR cell therapies across the 8MM, challenges that currently face CAR cell therapies, and future directions for CAR cell therapies
– Call-outs of key information and details
– Insight from GlobalData’s specialist oncology analysts.

Reasons to buy

– Develop business strategies by understanding the challenges facing CAR cell therapies.
– Design development strategies by understanding innovative development strategies likely to improve CAR cell therapy perceptions and uptake in the future.
– Be acquainted with regulatory processes relevant to CAR cell therapies across the US, 5EU, Japan and China.
– Develop strategies by understanding expert perceptions of currently approved CAR cell therapies, challenges facing CAR cell therapies, and future directions of CAR cell therapy.

Filed in: Pharmaceutical
Publisher : GlobalData
More Reports
Title Price Buy Now

Pediatric Vaccines: Epidemiology Forecast to 2028

Pediatric Vaccines: Epidemiology Forecast to 2028 Summary The administration of a vaccine, referred to as vaccination, elicits an immune response that prevents an individual from developing a specific disease when exposed to the corresponding infectious agent in the future. A successful vaccination results in immunization, where the individual is deemed immune to the disease. Routine immunization programs aim to protect children at an early age, when they are the most vulnerable to disease. Prior to the discovery of vaccines, several infectious diseases claimed the lives of millions of children each year. GlobalData epidemiologists utilized comprehensive, country-specific vaccination rate data from nationally representative public health surveillance systems and databases to arrive at ......
$3995

Parkinson’s Disease and Behavioral Complications: PD Therapies Dominate First-in-Class Pipeline, with Novel Target Classes Demonstrating Potential Disease-Modifying Effects

Parkinson's Disease and Behavioral Complications: PD Therapies Dominate First-in-Class Pipeline, with Novel Target Classes Demonstrating Potential Disease-Modifying Effects Summary Parkinson's disease (PD), a progressive neurological disorder that affects movement control, is associated with considerable quality of life impairments and burden of care, particularly in the advanced disease stages. Cognitive and behavioral complications of PD are common. PD-associated dementia and PD-associated psychosis are both highly prevalent and associated with a large disease burden. There is a pressing unmet need within PD, PD-associated dementia, and PD-associated psychosis for more effective disease-modifying pharmacotherapies. Although current therapies can provide patients with symptomatic relie......
$6995

Obesity: Gut Hormone Receptors Retain Commercial Prominence

Obesity: Gut Hormone Receptors Retain Commercial Prominence Summary Obesity is a chronic and potentially fatal disease. The most prevalent metabolic disorder affecting people today, obesity requires multidisciplinary continuing treatment. Despite the market's clinical and regulatory challenges, the obesity pipeline is robust and contains a high level of diversity in both molecule types and molecular targets, which is in line with its multifactorial etiology. The primary concern within the market is the need for medications that adequately address the unmet clinical needs in the overweight and obese population, namely efficacious and safe therapies. This report assesses first-in-class innovation across the obesity pipeline. Scope - The obesity pipeline is robust and contains a high leve......
$6995

Hepatitis B: Competitive Landscape to 2027

Hepatitis B: Competitive Landscape to 2027 Summary Hepatitis B is a viral infection of the liver that can become chronic in young children, especially newborns to mothers with HBV infections, and people with compromised immune systems. Chronic hepatitis B is defined as measurable Hepatitis surface antigen (HBsAg) levels for more than six months after an acute infection. Despite the existence of prophylactic vaccines, hepatitis B remains a global public health threat, with approximately 257 million people worldwide living with chronic HBV infections. Chronic hepatitis B cannot be cured and patients have elevated risks of developing liver cirrhosis and hepatocellular carcinoma (HCC). This report provides an assessment of the pipeline, clinical, and commercial landscape of Hepatitis B. Ov......
$3495

Cognitive Impairment Global Clinical Trials Review, H1, 2019

Cognitive Impairment Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Cognitive Impairment Global Clinical Trials Review, H1, 2019" provides an overview of Cognitive Impairment clinical trials scenario. This report provides top line data relating to the clinical trials on Cognitive Impairment. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinic......
$2500

Cytomegalovirus (HHV-5) Infections Global Clinical Trials Review, H1, 2019

Cytomegalovirus (HHV-5) Infections Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Cytomegalovirus (HHV-5) Infections Global Clinical Trials Review, H1, 2019" provides an overview of Cytomegalovirus (HHV-5) Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Cytomegalovirus (HHV-5) Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using ......
$2500

Complicated Skin And Skin Structure Infections (cSSSI) Global Clinical Trials Review, H1, 2019

Complicated Skin And Skin Structure Infections (cSSSI) Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Complicated Skin And Skin Structure Infections (cSSSI) Global Clinical Trials Review, H1, 2019" provides an overview of Complicated Skin And Skin Structure Infections (cSSSI) clinical trials scenario. This report provides top line data relating to the clinical trials on Complicated Skin And Skin Structure Infections (cSSSI). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on n......
$2500

Chronic Spinal Cord Injury Global Clinical Trials Review, H1, 2019

Chronic Spinal Cord Injury Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Chronic Spinal Cord Injury Global Clinical Trials Review, H1, 2019" provides an overview of Chronic Spinal Cord Injury clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Spinal Cord Injury. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary databas......
$2500

Cryptococcosis Global Clinical Trials Review, H1, 2019

Cryptococcosis Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Cryptococcosis Global Clinical Trials Review, H1, 2019" provides an overview of Cryptococcosis clinical trials scenario. This report provides top line data relating to the clinical trials on Cryptococcosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clin......
$2500

Cognitive Impairment Associated With Schizophrenia (CIAS) Global Clinical Trials Review, H1, 2019

Cognitive Impairment Associated With Schizophrenia (CIAS) Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Cognitive Impairment Associated With Schizophrenia (CIAS) Global Clinical Trials Review, H1, 2019" provides an overview of Cognitive Impairment Associated With Schizophrenia (CIAS) clinical trials scenario. This report provides top line data relating to the clinical trials on Cognitive Impairment Associated With Schizophrenia (CIAS). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy